Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Bayer and Matsushita in Diagnostic Alliance

By HospiMedica staff writers
Posted on 01 Jun 2001
A long-term strategic business relationship to jointly develop, manufacture, and market diagnostic products has been announced by Bayer Corp. More...
(Tarrytown, NY, USA) and Matsushita Electric Industrial Co. (Osaka, Japan).

Under the agreement, Bayer Corporation, through its Business Group Diagnostics, will acquire rights for the sale and marketing of newly developed products and services for a broad range of applications for the diagnostics market, while Matsushita will be primarily responsible for the development and manufacture of new products and services. Combining Bayer's knowledge of the diagnostics customer and marketplace with the technologic expertise of Matsushita will enable both companies to develop products that meet the needs of the worldwide in vitro diagnostics market, estimated to reach US$25 billion by 2005.

"The relationship will leverage our combined strengths to develop innovative diagnostics solutions that meet the changing needs of the health-care market,” said Rolf Classen, president of Bayer Diagnostics. "We have already begun work on products for blood glucose monitoring through our Self Testing segment in Elkhart, Indiana, and the future opportunities are limitless.”





Related Links:
Bayer
Matsushita

Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.